Disclosed are 4-ureido-N-methyl-piperidine derivatives of formula (I) or a pharmaceutically acceptable salt thereof, wherein: R is aryl optionally substituted with one or more independent R103 substituents R1 is selected from the group consisting of hydroxyalkyl, alkyl, optionally substituted with one or more independent R103 substituents R4 is selected from the group consisting of alkyl, aryl, arylalkyl, optionally substituted with one or more independent R103 substituents or R4 is OR103 R6, R7, R8, R9 are selected from the group consisting of hydrogen and alkyl R103 is selected from the group consisting of hydrogen, cyano, nitro, -OR104, hydroxy, amino, alkyl, alkenyl, cycloalkyl, halogen, haloalkyl, alkoxy, alkoxyalkyl, aryl, arylalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, -C(O)R104, -C(O)OR104, -C(O)NR104R105, -NR104R105, -NR104S(O)2R105, -NR104C(O)R105, -S(O)2R104, -SR104 and -S(O)2NR104R105, and R104 and R105 are each independently selected from the group consisting of hydrogen, cyano, nitro, hydroxy, hydroxyalkyl, amino, alkyl, alkenyl, cycloalkyl, halogen, alkoxy, alkoxyalkyl, aryl, arylalkyl, heterocycloalkyl, heteroaryl and heteroarylalkyl. Also disclosed are representative compounds such as 1-methyl-3-((R)-1-(naphthalen-1-yl)ethyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea, 3-(1-(4-methoxynaphthalen-1-yl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea, 3-(1-(2,3-dichlorophenyl)ethyl)-1-(3-methoxybenzyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea, 3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea, 3-(1-(2-methoxynaphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea, 3-(2-cyclopropyl-1-(2,3-dichlorophenyl)ethyl)-1-(3-methoxybenzyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea, 3-(2-hydroxy-1-(naphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea, 1-ethyl-1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)-3-(3-(pyridin-3-yloxy)phenyl)propyl)urea, 1-methyl-1-(1-methylpiperidin-4-yl)-3-(3-morpholino-1-(na
